Perlegen Sciences, Inc. is a private company that uses high-density, whole-wafer microarray technology in combination with new approaches to sample preparation to scan entire human genomes. The company's first objective is to read 50 different human genomes at a single base resolution, discovering and analyzing the patterns of genetic variation between them. Then, using what it has learned about genome-wide haplotype patterns by reading the first 50 genomes, Perlegen will scan the DNA of thousands of individuals with pharmaceutical partners, in order to associate genetic haplotypes with disease and drug response. The company will also conduct downstream research aimed at elucidating the biology underlying those genotype-phenotype associations in order to accelerate the discovery of new drugs and the modification of existing treatments.

Mountain View, California

Pfizer, Inc. Pfizer Inc is a research-based, global pharmaceutical company. We discover and develop innovative, value-added products that improve the quality of life of people around the world and help them enjoy longer, healthier, and more productive lives. The company has three business segments: health care, animal health and consumer health care. Our products are available in more than 150 countries.

New York, New York

Pharmacia Corporation Pharmacia is a top-tier global pharmaceutical company. We have built a portfolio of outstanding products, led by our key growth drivers: CELEBREX® (celecoxib capsules), CAMPTOSAR® (irinotecan hydrochloride injection), XALATAN® (latanoprost ophthalmic solution), DETROL®LA (tolterodine tartrate extended release capsules), and ZYVOX™ (linezolid injection, tablets, and for oral suspension).   Acquisition by Pfizer, Inc. announced in April 2003.


Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer and atherosclerosis. The company's products are rationally designed, ring-shaped small molecules called texaphyrins that disrupt the bioenergetic processes of diseased cells, such as cancer and atherosclerotic plaque. When activated by various forms of energy, including X-ray and light, these texaphyrins can help to reduce or eliminate the diseased tissue.

Sunnyvale, California

PharmaNetics, Inc., a leading biotech company, conceived the term "theranostics," defining an emerging new field of medicine that enables physicians to monitor the effect of antithrombotic agents in patients being treated for angina, myocardial infarction (heart attack), stroke, and pulmonary and arterial emboli. The Company develops, manufactures and markets rapid turnaround diagnostics to assess blood clot formation and dissolution. PharmaNetics develops tests based on its proprietary, dry chemistry Thrombolytic Assessment System for its principal target market of managing powerful new drug compounds, some of which may have narrow therapeutic ranges, as well as for monitoring routine anticoagulants.

Raleigh, North Carolina

PharmRx offers point-of-care, on-demand pharmacy services and diagnostic testing delivered through a robust software platform designed to improve patient compliance, medical outcomes and optimize per-patient revenue.

Contact:
Michael Russin
CEO
1050 N. Hermitage Ave, #3
Chicago, IL 60622
USA
  952-221-0506
  marussin@pharmrxgroup.com
Plexxikon is a leader in the discovery and development of novel small molecule pharmaceuticals to treat human disease. Since operations commenced June 2001, Plexxikon has applied its proprietary platform technology to identify and build a portfolio of product opportunities for therapeutic indications in metabolic disorders, cardiovascular disease, inflammation and oncology. Current Plexxikon programs address disease targets that are already validated in humans, have clear clinical development paths for significant unmet markets, and demonstrate Plexxikon's capability to address side effects and/or enhance the therapeutic profile of current drug treatments. Plexxikon's discovery process utilizes a number of technologies, including Plexxikon's Scaffold-Based Drug Discovery™ platform. This discovery platform involves structural screening and analysis as one key component providing a significant competitive advantage to other drug discovery approaches. Structural screening is applied at the earliest point in lead finding to address current challenges in pharmaceutical drug discovery today – by enabling the mining of novel chemical space, applying a unique quality filter, and by providing a roadmap for lead discovery and development chemistry.

91 Bolivar Drive
Berkeley, California 94710
  510.647.4000
  info@plexxikon.com

Following the sale of substantially all the assets and selected liabilities of its BBI Diagnostics and BBI Biotech Divisions to SeraCare Life Sciences, Inc. on September 14, 2004, Boston Biomedica changed its name to Pressure BioSciences, Inc (PBI). PBI is a publicly traded, early-stage company focused on the development of a novel technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (35,000 psi and greater) to control bio- molecular interactions. PBI currently holds 13 US and foreign patents covering multiple applications of PCT in the life sciences field, including in such areas as genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics, and protein purification. PBI owns a 30% passive investment in Source Scientific, LLC, an instrumentation company that develops and manufactures PBI's PCT equipment, as well as a 4.45% passive investment in Panacos Pharmaceuticals, an antiviral drug discovery and development company.

375 West Street
West Bridgewater, Massachusetts 02379
  (800) 676-1881
  info@bbii.com

Proneuron is a biopharmaceutical company developing cell therapies and other treatment modalities for neurological, ophthalmological and immune-related disorders such as spinal cord injury, multiple sclerosis, glaucoma, Parkinson's and Alzheimer's diseases. Proneuron's unique technologies, developed at the Weizmann Institute, are based on the modulation of natural mechanisms within the body to address currently incurable disorders.

Ness-Ziona, Israel

Manufacturer and Distributor of IVD. Research and Development. Manufacturer of reader and analyzer of IVD (lateral flow). Specifically toxicology. Looking for international distributors or co-operation partners.

Tuellinger Str. 36a
Loerrach, Germany 79539
  +4976215789517
  christoph.protzek@protzek.info
Purdue is part of an international group of associated independent companies engaged in the research, development, production, sales, and licensing of both prescription and over-the-counter medicines and hospital products. The company seeks to continually develop and sell new, high-quality, innovative pharmaceutical preparations, which together with clinical data and medical education create new value for patients and the health care system. Our sales, marketing, and medical education professionals provide the healthcare community with comprehensive educational materials and programs relating to Purdue products. These products include OxyContin® (oxycodone HCl controlled-release) Tablets, MS Contin® (morphine sulfate controlled-release) Tablets, Uniphyl® (theophylline, anhydrous) Tablets, Chirocaine® (levobupivacaine injection), and the popular over-the-counter Senokot® Laxatives, Betadine® Microbicides, and Betadine® Brand Antibiotics.

Stamford, Connecticut

India's largest pharmaceutical company, Ranbaxy Laboratories Limited, is today well positioned in its quest to become a research-based international pharmaceutical company. Ranbaxy is amongst the top pharmaceutical companies in the world. It has been rated the 11th largest Generic Company Worldwide. The Company exports its products to over 70 countries with ground operations in 25 and manufacturing facilities in 7 countries.

Princeton, New Jersey

Ribapharm is a biopharmaceutical company that seeks to discover, develop, acquire and commercialize innovative products for the treatment of significant unmet medical needs, principally in the antiviral and anticancer areas. NOTE: Acquisition by ICN Pharmaceuticals announced 25 August 2003.

Costa Mesa, California

Rubicon Genomics’ novel OmniPlexTM technology reformats naturally-occurring chromosomes into new molecules called Plexisomes™. Plexisomes represent an entire genome as DNA units of controlled length that can be amplified in a highly multiplexed fashion. The unique structure of Plexisomes allows large regions of a genome to be analyzed up to hundreds of times more efficiently than cloning or PCR. Hundreds of thousands of DNA bases can be amplified simultaneously from single loci or multiple loci.

Ann Arbor, Michigan

Salix Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to gastroenterologists and their patients.

Our "search and development" efforts are designed to identify and acquire late-stage and/or marketed proprietary pharmaceutical products that have an existing base of safety and efficacy data for the treatment of gastrointestinal disease. This focus on late-stage products serves to reduce the risk, time and expense Salix invests in products compared to the investment typically associated with the research and early development phases of pharmaceutical products.

Salix has a direct sales force to promote its products to the fastest- adopting, highest-prescribing physicians in the U.S. responsible for treating gastrointestinal disease. We believe that our specialty sales force – and the high level of service we are able to provide - allows us to capitalize on the opportunity to build a franchise with the gastroenterology community. We also believe that our specialty sales force allows us to attain the higher profit margins and benefits of direct control over distribution that comes with selling products directly.

Raleigh, North Caroliina
  888-802-9956
  investor.relations@salixpharm.com

SangStat Medical Corporation is a global biotechnology company focused on immunology and working to discover, develop and market high value therapeutic products in the autoimmune, hematology/oncology and immunosuppression areas. NOTE: Acquisition by Genzyme Corporation announced 8/04/2003.

6300 Dumbarton Circle
Fremont, California 94555
  510-789-4300
  bmartin@sangstat.com

sanofi-aventis Group The sanofi-aventis Group is the world’s 3rd largest pharmaceutical company, ranking number 1 in Europe. Backed by a world-class R&D organization, sanofi-aventis is developing leading positions in seven major therapeutic areas: cardiovascular disease, thrombosis, oncology, diabetes, central nervous system, internal medicine, and vaccines. The sanofi-aventis Group is listed in Paris and New York.

New York, New York
  info@sanofi-aventis.com

As a worldwide, research-based pharmaceutical company, we are engaged in the discovery, development, manufacturing and marketing of new therapies and treatment programs that can improve people's health and extend their lives. Our primary business involves prescription products in core product categories, including: Allergy and respiratory, Anti-infective and anticancer, Cardiovasculars, Dermatologicals, Central nervous system and other disorders.

Kenilworth, New Jersey

Scios Inc. is a biopharmaceutical company developing novel drugs for the potential treatment of cardiovascular and inflammatory diseases. We are distinguished by our disease-based technology platform which integrates expertise in protein biology with computational and medicinal chemistry to identify novel targets and rationally design small-molecule compounds. Scios has received approval from the U.S. Food and Drug Administration to market Natrecor (nesiritide) for the treatment of patients with acutely decompensated congestive heart failure who have shortness of breath (dyspnea) at rest or with minimal activity. Natrecor is a new drug class, human B-type Natriuretic Peptides, made available as a therapeutic in the United States.

Sunnyvale, California

Serologicals' antibody-based products are used as the active ingredients in therapeutic products for the treatment and management of diseases, such as Rh incompatibility in newborns, rabies and hepatitis and in diagnostic products such as blood typing reagents and diagnostic test kits. The Company also provides a variety of proteins used in the manufacturing of diagnostic reagents and genetically engineered biopharmaceuticals.

Norcross, Georgia

SICOR Inc. is a vertically integrated, multinational pharmaceutical company that focuses on generic finished dosage injectable pharmaceuticals, active pharmaceutical ingredients, or APIs, and generic biopharmaceuticals. Using internal research and development capabilities, together with operational flexibility and manufacturing and regulatory expertise, SICOR is able to take a wide variety of products from the laboratory to the worldwide market. Leveraging these capabilities, SICOR concentrates on products and technologies that present significant barriers to entry or offer first-to-market opportunities. SICOR operates several manufacturing facilities in the U.S., Western and Eastern Europe and Mexico, while maintaining its corporate headquarters in Irvine, California.

Irvine, California

SkyePharma PLC (located in London, UK) develops pharmaceutical products benefiting from world-leading drug delivery technologies that provide easier-to-use and more effective drug formulations. Currently, there are nine approved products that incorporate three of SkyePharma's five technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilization capabilities. SkyePharma's US subsidiary, SkyePharma Inc. (formerly DepoTech Corporation) develops and manufactures injectable, sustained-release therapeutic products.

San Diego, California

Sonus Pharmaceuticals, Inc. is focused on the development of novel drugs for the treatment of cancer that offer improved administration, tolerability, safety and effectiveness. The Company continues to advance the clinical and regulatory development of TOCOSOL Paclitaxel and is in the process of finalizing Phase 3 clinical testing plans for review by the U.S. Food and Drug Administration. With the promising clinical results to date, Sonus believes that TOCOSOL Paclitaxel may potentially offer a safer and more effective alternative paclitaxel therapy for cancer patients that is better tolerated and easier-to-use. In addition to executing the plans for TOCOSOL Paclitaxel, the Company remains focused on driving product and corporate development activities towards building and expanding its pipeline of oncology product candidates.

22026 20th Avenue SE
Bothell, Washington 98021
  425.487.9500
  info@sonuspharma.com

Spectrum Pharmaceuticals is an oncology-focused pharmaceutical company engaged in the business of acquiring, developing and commercializing proprietary drug products which have a primary focus on the treatment of cancer and related disorders as well as generic drug products for various indications. The Company's lead drug, satraplatin, is a phase 3 oral, anti-cancer drug being co-developed with GPC Biotech AG, and has been granted fast-track status by the United States Food and Drug Administration (FDA). Elsamitrucin, a phase 2 drug, will initially target non-Hodgkin's lymphoma. EOquin(TM), a phase 2 drug, is being studied in the treatment of superficial bladder cancer. SPI-153 (formerly, D-63153), a phase 2 drug, is a 4th generation LHRH antagonist with the potential to treat hormone-dependent cancers as well as benign proliferative disorders, such as benign prostatic hypertrophy and endometriosis. In addition, the Company has two Abbreviated New Drug Applications for carboplatin and fluconazole, the generic equivalents of Paraplatin® and Diflucan®, respectively, under active review at the FDA.

157 Technology Drive
Irvine, California 92618
  (949) 788-6700
  info@spectrumpharm.com

STADA Pharmaceutical USA, INC. is a wholly owned subsidiary of STADA Arzneimittel AG. Headquartered in Cranbury, New Jersey is a leading pharmaceutical company specializing in the development and marketing of generic and branded pharmaceutical products for the U.S. Pharmaceutical market. The generic portfolio covers all major therapeutic areas with some emphasis on antibiotics. The product development strategy is supported by active development of new products, licensing and acquisitions. And, the company's foreseeable opportunities clearly exceed initial expectations by responsiveness to market needs. STADA outsources all of its manufacturing from world class contract manufacturers in the U.S. and Europe. This allows us to maintain the highest level of flexibility and market responsiveness, a true benefit for our customers. Distribution of our products has been outsourced as well, allowing for state of the art innovations in distribution that are aimed at optimizing service levels. STADA Pharmaceuticals, Inc. distributes its products through wholesalers, chain drug stores, retail pharmacies, mail order companies, managed Care organizations, hospital groups, nursing home providers and government agencies.

5 Cedar Brook Drive
Cranbury, New Jersey 08512
  609.409.5999
  info@stadausa.com
SuperGen is a pharmaceutical company whose mission is to prolong, improve the quality of and ultimately, save the lives of those people afflicted with life-threatening diseases, especially cancer. The company possesses a broad portfolio of proprietary cancer therapies that target a variety of solid tumors, hematological malignancies and blood disorders, offering renewed hope to patients who suffer from these illnesses. The company is led by a seasoned management team with extensive experience in all aspects of the oncology pharmaceutical industry.

Dublin, California

Prescription drug medications are timed released providing a medicine plan scheduled by a pharmacy in a locked medicine cabinet for senior citizens in assisted living and adult day care community housing centers to provide accurate and reliable prescription drugs and medication administration by TabSafe Medical Services, Inc.

Alpharetta, Georgia
  cgillig@tabsafe.com
Taro markets a broad range of prescription and over-the-counter products in the United States. We are a leading manufacturer and supplier of topical dermatological products and also have a growing line of solid dosage form products used mainly in cardiology and neurology.

Hawthorne, New York

We are looking for distributors and sale reps in western Canada (based in B.C and/or Alberta), Quebec and the U.S.A. TeleMED has been a leader in Vital sign Data management for the passed 12 years. Over 3000 professional medical users, managing over 1 million tests annually.

Contact:
Asa Lebel
President and CEO
1110 Finch Ave West #16
Toronto, Canada M3J2T2
  416-665-8016
  asalebel@telemeddm.com
Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 35 pharmaceutical companies and among the largest generic pharmaceutical companies in the world. Over 80% of Teva's sales are in North America and Europe. The company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients.

North Wales, Pennsylvania

The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve specialized care. The Company markets Angiomax® (bivalirudin), an anticoagulant approved for use in patients undergoing coronary angioplasty procedures. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 150 professionals. In addition to the approved Angiomax product, The Medicines Company is developing clevidipine, a short-acting calcium channel blocker. The Medicines Company is also conducting significant clinical research to study potential additional indications for Angiomax use.

8 Campus Drive
Parsippany, New Jersey 07054
  (973) 656-1616

Titan Pharmaceuticals, Inc. is a diversified biopharmaceutical company focused on the development and commercialization of novel treatments for central nervous system (CNS) disorders, cancer and other serious and life-threatening diseases. The company’s numerous products in development utilize innovative technologies that have the potential to significantly improve the treatment of these diseases. Titan also establishes important partnerships with multinational pharmaceutical companies and government institutions for the development of its products.

South San Francisco, California

Transkaryotic Therapies Inc. TKT is a leading biotechnology company developing and commercializing human proteins for a broad range of diseases, with a major focus on rare genetic diseases. TKT currently markets one product, Replagal(TM) (agalsidase alfa) for the treatment of Fabry Disease in the European Union and certain other countries and has four products in clinical testing. TKT is headquartered in Cambridge, Massachusetts and has a majority owned subsidiary in Sweden, TKT Europe-5S AB, which is responsible for European sales and marketing activities.

Cambridge, Massachusetts

Triangle Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the development of new antiviral drug candidates, with a particular focus on therapies for the human immunodeficiency virus (HIV) and the hepatitis B virus. Triangle's proprietary drug candidates under development for HIV and/or hepatitis B include Coviracil(R) (emtricitabine), amdoxovir (formerly DAPD) and clevudine (formerly L-FMAU).

Durham, North Carolina

RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.RepFinder 2 - available on the Apple App Store for iPhone and iPad.